Skip to main content
Clinical Trials/IRCT201701092639N20
IRCT201701092639N20
Completed
Phase 2

Evaluation of efficacy of topiramate alone and topiramate with supplement vitamin D3 on monthly frequency, severity, and disability score of headaches in 5-15 year old migraineur children without vitamin D3 deficiency

Shahid Sadoughi University of Medical Sciences, Yazd, Iran0 sites60 target enrollmentTBD

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Migraine.
Sponsor
Shahid Sadoughi University of Medical Sciences, Yazd, Iran
Enrollment
60
Status
Completed
Last Updated
8 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
8 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Shahid Sadoughi University of Medical Sciences, Yazd, Iran

Eligibility Criteria

Inclusion Criteria

  • children aged 5\-15 years old; having migraine headache based on International Headache Society Criteria; having one or more headache attack per week; having moderate or severe headache disability; having normal hemoglobin level and mean corpuscular volume (hemoglobin level more than 11\.5g/dl and mean corpuscular volume more than 80 fL); having sufficient vitamin D3 level ( more than 30 ng/mL); have not received vitamin D3 combinations within the past two months; not used any migraine preventive therapy. Exclusion criteria: secondary headaches such as epilepsy or other neurologic disorders; irregular drugs usage; discontinuation of drugs usage for more than one week; allergy to topiramat or vitamin D3; vitamin D3 level more than 80 ng/mL.

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Not specified

Similar Trials